Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

3(43%)

Results Posted

150%(3 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_2

14%

Ph phase_1

29%

Ph phase_3

43%

Ph early_phase_1

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Early Phase 1First-in-human

1(14.3%)

Phase 1Safety & dosage

2(28.6%)

Phase 2Efficacy & side effects

1(14.3%)

Phase 3Large-scale testing

3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(2)

Terminated(1)

Other(1)

Detailed Status

Completed2

Recruiting2

Terminated1

unknown1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (14.3%)

Phase 12 (28.6%)

Phase 21 (14.3%)

Phase 33 (42.9%)

Trials by Status

terminated114%

completed229%

recruiting229%

unknown114%

active_not_recruiting114%

Recent Activity

3 active trials

Showing 5 of 7

recruitingphase_3

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

NCT06431776

recruitingearly_phase_1

Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei

NCT07341360

active_not_recruitingphase_3

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293

terminatedphase_3

Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

NCT03482752

completedphase_2

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

NCT02702180

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT06431776Phase 3

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Recruiting

NCT07341360Early Phase 1

Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei

Recruiting

NCT04544293Phase 3

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active Not Recruiting

NCT03482752Phase 3

Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

Terminated

NCT02702180Phase 2

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

Completed

NCT05501340Phase 1

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Unknown

NCT02468908Phase 1

Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7